Tatva Chintan Pharma Chem Limited (TATVA) Fair Value & Analysis
Basic Materials · IN · Market cap ₹29.2B
Fair value as of: Aug 13, 2026
From 16 valuation models · updated 4 days ago
Share price +18.0% over the past month.
Below-average quality, and screening another 85% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹321.57). The favourable scenario is already priced in.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹636.37 – ₹2,863 · fair‑value band ₹229.22 – ₹321.57 · the ₹1,686 price screens above the ₹247.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Tatva Chintan Pharma Chem Limited (TATVA) currently trades at ₹1,686, while our model-based Fair Value estimate is ₹247.36, implying the stock looks roughly 85.3% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Tatva Chintan Pharma Chem Limited generated revenue of ₹5.1B at a net margin of 8.3%. Revenue grew 24.4% year over year. It earns a return on equity of 5.5%. Net debt stands at ₹1.1B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹229.22 (bear case) to ₹321.57 (bull case); at ₹1,686, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 83% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -68% fair-value upside, at -85%, TATVA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Multiples (₹305.62) versus Dividend Discount (₹16.10). Highest evidence: Residual Income (76).
Notify me when TATVA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally.
Full company description
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Tatva Chintan Pharma Chem Limited reported revenue of ₹5.1B in FY2026 versus ₹4.3B in FY2022, a compound +3.9%/yr. Reported net income was ₹421M in FY2026, compounding −18.6%/yr from FY2022.
TATVA screens 85% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 672 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $479.43 | $222.03 | -54% |
| Wanhua Chemical Group 600309 | ¥75.06 | ¥68.03 | -9% |
| Novozymes A/S NSISB | kr 416.10 | kr 170.02 | -59% |
| Asian Paints Limited ASIANPAINT | ₹2,756 | ₹664.51 | -76% |
| Solar Industries India Limited SOLARINDS | ₹18,730 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,702 | ₹351.84 | -79% |
| PT Chandra Asri Pacific Tbk TPIA | 2,160 IDR | 2,322 IDR | +8% |
| Berger Paints India Limited BERGEPAINT | ₹559.80 | ₹154.46 | -72% |
| Gujarat Fluorochemicals Limited FLUOROCHEM | ₹4,566 | ₹836.47 | -82% |
| Himadri Speciality Chemical Limited HSCL | ₹778.15 | ₹248.63 | -68% |
Compare Tatva Chintan Pharma Chem Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Tatva Chintan Pharma Chem Limited (TATVA) overvalued or undervalued?
What is the fair value of TATVA?
What is the quality score of TATVA?
What is the revenue of Tatva Chintan Pharma Chem Limited (TATVA)?
What is the net profit margin of TATVA?
Does Tatva Chintan Pharma Chem Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tatva Chintan Pharma Chem Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.